N-benzyladriamycin-14-valerate versus progressively doxorubicin-resistant murine tumours: cellular pharmacology and characterisation of cross-resistance in vitro and in vivo.

N-Benzyladriamycin-14-valerate (AD198) is a novel lipophilic anthracycline with greater in vivo antitumour activity than doxorubicin (DOX) in experimental model systems. Using sensitive and progressively DOX-resistant L1210 mouse leukaemia and B16-BL6 mouse melanoma lines, we have determined the cel...

Full description

Saved in:
Bibliographic Details
Main Authors: Ganapathi, R., Grabowski, D., Sweatman, T. W., Seshadri, R., Israel, M.
Format: Artigo
Language:Inglês
Published: Nature Publishing Group 1989
Subjects:
Research Article
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC2247277/
https://ncbi.nlm.nih.gov/pubmed/2605093
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items